---
document_datetime: 2023-09-21 19:59:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/nonafact-epar-procedural-steps-taken-authorisation_en.pdf
document_name: nonafact-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 2.3013736
conversion_datetime: 2025-12-17 08:12:17.822474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INF'ORMATION ON TTIE PROCEDURE

## 1. Submission  of the dossier

The company  Sanquin, CLB, Products Division submitted  on 24 lantnry 2000 an application for Marketing  Authorisation  to the European  Agency for the Evaluation  of Medicinal Products  (EMEA) for Nonafact,  in accordance  with the centralised  procedure falling within  the scope of Part A of the Annex  to Council Regulation  No (EEC) 2309193 of 22lvly  1993, as amended.

The Rapporteur  and Co-Rapportew appointed by the CHMP  were:

<!-- image -->

) a a Rapporteur:  Dr. Hans van Bronswijk Co-Rapporteur: Dr. Tomas Salmonson Licensing status: The product  was not licensed in any country at the time of submission  of the application. Steps taken for the assessment of the product The procedure  started  on 18 February  2000. The Rapporteur's first Assessment  Report  was circulated to all CPMP members on 28 April 2000. The Co-Rapporteur's  first Assessment  Report was circulated to all CPMP Members  on 28 April 2000. During the meeting  on27-29 June 2000 the CPMP agreed  on the consolidated  List of  Questions to be sent to the company.  The final consolidated  List of  Questions  was sent to the company  on 29 June 2000. The company submitted the responses to the CPMP consolidated  List of Questions  on 11 December 2000. The Rapporteur circulated Assessment Report on the company's responses  to the List of  Questions  to all CPMP  members on 22 January 2001. The company  submitted  written responses  to outstanding points  identified in the response Assessment  Report on 16 February 2001. The Rapporleur  circulated  the assessment of the responses  to the outstanding points on 19 February 2001. During the meeting on 27-28 February 2001 and I March 2001 the CPMP, in the light of the overall data submitted  and the scientific  discussion within the Committee,  issued a positive opinion for granting  a Marketing  Authorisation  to Nonafact on I March 2001. The CPMP opinion was forwarded,  in all official  languages  of the European Unioq  to the European commission,  which adopted the corresponding  Decisions  on 3 July 2001. Medicinal product no longer authorised

<!-- image -->